This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.
Nature nanotechnology · 2019
Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.
British journal of pharmacology · 2018
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Molecular therapy : the journal of the American Society of Gene Therapy · 2011
Latest funding
- $914,175
Activation of the chronic endothelial function reserve for the prevention and regression of aortopathies.
CIHR · 2024 · Co-investigator
- $150,000
High Resolution ESI Mass Spectrometer
NSERC · 2018 · Co-investigator
- $359,850
Side effect-free cathepsin K targeting drugs for skeletal diseases
CIHR · 2017 · Principal investigator
3 publications.
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.
Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X, Hope MJ, Madden TD, Mui BL, Semple SC, Tam YK, Ciufolini M, Witzigmann D, Kulkarni JA, van der Meel R, Cullis PR
Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.
Panwar P, Law S, Jamroz A, Azizi P, Zhang D, Ciufolini M, Brömme D
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR
Activation of the chronic endothelial function reserve for the prevention and regression of aortopathies.
Principal investigators: Bernatchez, Pascal N
Keywords: Aneurysm; Angiotensin; Aorta; Endothelium; Losartan; Marfan Syndrome; Nitric Oxide
High Resolution ESI Mass Spectrometer
Principal investigators: Ryan, Katherine
Side effect-free cathepsin K targeting drugs for skeletal diseases
Principal investigators: Bromme, Dieter; Percival, Michael D; Ciufolini, Marco A
Keywords: Arthritis; Bone Cancer; Cathepsin K; Collagen; Dose Response; Drug Development; Ectosteric Inhibitors; Protease; Protease Inhibitors; Tanshinones
Synthesis of a pharmaceutical product
Principal investigators: Ciufolini, Marco
Lipid nanomedicines for health and disease
Principal investigators: Cullis, Pieter R
Keywords: Anticancer; Drug Delivery System; Gene Therapy; Immunosuppressant; Lipid Nanoparticles; Mrna; Nanomedicine; Sirna; Small Molecule Drugs; Trigger Release
Synthesis of Complex Natural Products
Principal investigators: Ciufolini, Marco
Upgrade to UBC-Chemistry Departmental NMR Facility
Principal investigators: Gates, Derek
Design of Lipid Nanoparticle Systems for the Systemic Delivery of siRNA
Principal investigators: Cullis, Pieter R
Keywords: Cancer; Cationic Lipid; Drug Delivery; Endosomal Release; Gene Silencing; Intracellular Delivery; Lipid Nanoparticle; Liposome; Sirna; Targeting
MALDI-TOF mass spectrometer
Principal investigators: MacLachlan, Mark
Synthetic Organic Chemistry
Principal investigators: Ciufolini, Marco
Keywords: CRC
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.